NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

NeoGenomics Reports Second Quarter 2025 Results

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

  • NeoLINK Login
  • Investors
Search
LogoNeoLINK Login
Menu
  • Home
  • Providers
    Providers
    • Oncology solutions
      • Lung cancer
      • Breast cancer
      • Colorectal cancer
      • Gastric cancer
      • Hematologic cancers
    • Pathology solutions
      • Test search
      • Lab services
    • Client support & resources
      • Certifications & licenses
      • Test requisition forms
  • Partners
    Partners
    • Biopharma services
    • Oncology data solutions
    • Regulatory support
  • Patients
  • About NeoGenomics
    About NeoGenomics
    • Who we are
    • Scientific contributions
    • Careers
    • Privacy
    • Contact us
  • Billing
    Billing
    • For clinicians
    • For patients
    • Financial assistance
    • Pay your bill online
  • Test Search
  • Investors
Test Search
Skip to main content Skip to section navigation Skip to footer
NeoGenomics, Inc. IR Overview
  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Literature
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Info
    • Quote
    • Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • CSR
    • 2025 report
    • Inaugural Report

Press Releases

Investors News & Events Press Releases
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Literature
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Info
    • Quote
    • Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • CSR
    • 2025 report
    • Inaugural Report
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Literature
  • Email Alerts
Apr 22, 2025 7:05 am EDT
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
Apr 8, 2025 7:05 am EDT
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
Apr 7, 2025 7:05 am EDT
NeoGenomics Completes Acquisition of Pathline
Apr 1, 2025 7:05 am EDT
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
Mar 18, 2025 7:05 am EDT
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
Mar 10, 2025 7:00 am EDT
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
Feb 24, 2025 7:05 am EST
NeoGenomics to Participate in Upcoming Investor Conferences
Feb 18, 2025 7:05 am EST
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
Jan 29, 2025 8:05 am EST
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
Jan 15, 2025 7:05 am EST
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • rss_feedRSS News Feed
  • account_treeSitemap
©2025 NeoGenomics, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement
  • Manage Cookie Preferences